Get the Weekly Intelligence Brief — top committee picks every Sunday.

INCY vs TEVA

Incyte vs Teva Pharmaceutical Industries Limited — AI-powered side-by-side comparison
INCY
Incyte
72
Buy
VS
TEVA
Teva Pharmaceutical Industries Limited
55
Watch
MetricINCYTEVA
AI Score 72 55
Price $121.08 $36.49
P/E Ratio 14.89× 57.19×
ROE 24.9% 17.8%
Revenue Growth YoY
Gross Margin 92.6% 52.5%
Debt / Equity 0.01× 2.16×
Dividend Yield 0.0% 0.0%
RSI (14) 56.2 77.8
Beta 0.769 0.864
Expected Upside

AI Committee View

Current Innellis committee reasoning for INCY versus TEVA.
INCY leads by 17 points.

INCY scores 72/100 (Buy) versus TEVA at 55/100 (Watch).

INCY Committee View
100% agreement
6 analysts

The primary driver is revenue growing 26.9% yoy -- genuine top-line momentum. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.

Bull Case
  • ROE of 29.6% shows genuine earnings power backing the valuation — Value
  • Revenue growing 26.9% YoY -- genuine top-line momentum — Growth
  • EPS growing 80.3% YoY — Growth
Bear Case
  • MACD histogram negative -- bearish momentum — Technical
  • Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
TEVA Committee View
50% agreement
6 analysts

The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.63 across 21 articles, 14d). Value Analyst remains cautious — p/e of 57.5 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
  • P/E of 57.5 is expensive by classic value standards — Value
  • Price-to-book of 4.9x prices in significant intangible value — Value
  • Debt-to-equity of 2.12 adds balance-sheet risk to the value case — Value
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
INCY Full Analysis TEVA Full Analysis